Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Asthma inhaler showdown: new combo vs. standard care

NCT ID NCT05735431

Disease control Sponsor: Eurofarma Laboratorios S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a new lower-dose asthma inhaler (formoterol 6 mcg/fluticasone 125 mcg) works as well as an existing one (formoterol 6 mcg/budesonide 200 mcg) for people aged 12 and older with moderate asthma. The trial was withdrawn before any participants were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients of both sexes who meet all of the following criteria will be included in the study: * Signature of the Informed Consent Term (ICF) for people over 18 years and, when applicable, signature of the Informed Assent Form (IAF) by the participant under 18 years of age and the ICF by the representative before carrying out any study procedure. * Age ≥ 12 years. * History of recurrent symptoms suggestive of asthma (cough, wheezing, shortness of breath, and/or chest tightness). * Previous medical diagnosis of asthma. Exclusion Criteria: Patients who meet at least one of the following criteria will be excluded from the study: * Occurrence of moderate to serious asthma exacerbation within 90 days prior to initiation of study treatment. * Presence of acute or chronic symptomatic respiratory tract infection. * Body mass index (BMI) ≥ 38 kg/m2. * Use of long-acting anticholinergic drug (LAMA) in the last six (06) months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate asthma

Contacts and locations

Locations

  • Eurofarma Laboratorios S.A

    São Paulo, 06696-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.